Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

477
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
477
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.2K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

295
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
295
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

334
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
334
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

293
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
293
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

411
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
411

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tailoring heart failure management in cardiac amyloidosis.

Heart failure reviews·2026
Same author

Diagnostic and therapeutic challenges in rare hematologic entities: monoclonal gammopathy of thrombotic and bleeding significance.

Haematologica·2026
Same author

The Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma With Renal Impairment: A Systematic Review.

American journal of hematology·2026
Same author

Incidence of second primary malignancies in patients with AL amyloidosis and the impact of disease stage and therapies.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis·2026
Same author

Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma.

Blood cancer journal·2026
Same author

Enhanced dynamic risk stratification of smoldering multiple myeloma.

Nature medicine·2026

Related Experiment Video

Updated: Mar 12, 2026

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

1.0K

Current therapy guidelines for Waldenstrom's macroglobulinaemia.

Efstathios Kastritis1, Meletios A Dimopoulos1

  • 1Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.

Best Practice & Research. Clinical Haematology
|November 10, 2016
PubMed
Summary

Waldenstrom's macroglobulinaemia (WM) treatment evolves with new targeted therapies like ibrutinib. Treatment decisions for this B-cell neoplasm now consider genetic mutations and patient factors for personalized care.

Keywords:
BortezomibCarfilzomibFludarabineIbrutinibRituximab

More Related Videos

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
10:35

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

8.7K
Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations
10:41

Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations

Published on: March 29, 2017

12.4K

Related Experiment Videos

Last Updated: Mar 12, 2026

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

1.0K
Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
10:35

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

8.7K
Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations
10:41

Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations

Published on: March 29, 2017

12.4K

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Waldenstrom's macroglobulinaemia (WM) is a rare B-cell neoplasm characterized by lymphoplasmacytic infiltration of the bone marrow and secretion of monoclonal immunoglobulin M (IgM).
  • Established diagnostic and therapeutic criteria exist, but treatment recommendations are dynamic due to emerging therapeutic options and a deeper understanding of disease biology.
  • Treatment decisions are multifactorial, integrating disease-specific parameters (e.g., disease burden, IgM levels, cytopenias) with patient-specific factors (e.g., age, comorbidities, toxicity tolerance).

Purpose of the Study:

  • To review current treatment strategies for Waldenstrom's macroglobulinaemia (WM).
  • To discuss the impact of emerging therapies and genetic mutations on treatment decisions.
  • To highlight future directions in WM management.

Main Methods:

  • Review of current literature and clinical guidelines for Waldenstrom's macroglobulinaemia (WM) treatment.
  • Analysis of the role of chemo-immunotherapy combinations (e.g., rituximab-based regimens).
  • Evaluation of novel targeted therapies, including BTK inhibitors and other emerging agents.

Main Results:

  • Chemo-immunotherapy combinations involving rituximab are standard for most WM patients.
  • The BTK inhibitor ibrutinib represents a new therapeutic option for specific patient groups.
  • Emerging mutations (MYD88, CXCR4) are increasingly influencing treatment selection and response prediction.

Conclusions:

  • Current WM treatment relies on chemo-immunotherapy, with newer targeted agents like ibrutinib offering personalized options.
  • Understanding specific mutations (MYD88, CXCR4) is crucial for optimizing future WM therapy.
  • Ongoing research into novel agents (e.g., B-cell receptor inhibitors) holds promise for improved outcomes in WM.